Portal de Periódicos da CAPES

Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

2013; Elsevier BV; Volume: 25; Issue: 2 Linguagem: Inglês

10.1093/annonc/mdt540

1569-8041

Juan W. Valle, Junji Furuse, Mark Jitlal, Sandy Beare, Nobumasa Mizuno, Harpreet Wasan, John Bridgewater, Takuji Okusaka,

Oral and gingival health research

Two recent studies (ABC-02 [UK] and BT22 [Japan]) have demonstrated the superiority of cisplatin and gemcitabine (CisGem) chemotherapy over gemcitabine (Gem) alone for patients with pathologically proven advanced biliary tract cancer (BTC: cholangiocarcinoma, gallbladder and ampullary cancers). This pre-planned analysis evaluates the efficacy of CisGem with increased statistical power.